DNAH17-AS1: A Potential Drug Target and Biomarker (G100996295)

Target Name: DNAH17-AS1

NCBI ID: G100996295

DNAH17-AS1

Other Name(s): DNAH17 antisense RNA 1

DNAH17-AS1: A Potential Drug Target and Biomarker

DNAH17-AS1, also known as HDAC17, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology make it an attractive target for drug development due to its ability to regulate the expression of genes and its involvement in various cellular processes.

Structure and Function

DNAH17-AS1 is a small non-coding RNA molecule that contains 17 exons and is expressed in various tissues and cells of the body. It belongs to the HIDN family of RNA-binding proteins and has been shown to play a role in the regulation of gene expression and cellular processes, including cell growth, apoptosis, and inflammation.

One of the most significant features of DNAH17-AS1 is its ability to interact with DNA. This interaction is mediated by its C-terminal region, which contains a conserved G-C loop and a T-rich region. The G-C loop provides a binding site for DNA, while the T-rich region is responsible for the formation of a stem-loop, which can interact with DNA in a similar way to a stem-loop from RNA.

DNAH17-AS1 has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences. For example, studies have shown that DNAH17-AS1 can interact with the tumor suppressor gene P53 and can inhibit its activity. This interaction between DNAH17-AS1 and P53 suggests that it may be a useful biomarker for the diagnosis and treatment of cancer.

Another potential mechanism by which DNAH17-AS1 may contribute to cancer development is its role in the regulation of apoptosis. DNAH17-AS1 has been shown to play a negative role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. Its ability to interact with the transcription factor NF-kappa-B and the protein p53 suggests that it may be involved in the regulation of apoptosis by these factors.

Drug Development

The potential drug targets for DNAH17-AS1 are numerous and range from cancer therapies to central nervous system (CNS) disorders. One of the most promising areas of research is the development of small molecule inhibitors of DNAH17-AS1 that can be used to treat cancer.

One approach to drug development for DNAH17-AS1 inhibitors is to use a structure-based design strategy. This involves the synthesis of a library of potential inhibitors using DNAH17-AS1 as the target and a diverse set of molecules as a starting point. The most promising inhibitors are then screened for activity using various cellular assays, including cell-based assays and activity assays such as western blotting.

Another approach to drug development for DNAH17-AS1 inhibitors is to use a high-throughput screening (HTS) approach. This involves the screening of a large library of compounds for activity against DNAH17-AS1 using various cellular assays, including cell-based assays and activity assays. The most promising compounds are then further optimized and tested for activity in preclinical models of cancer.

While DNAH17-AS1 has the potential to be a drug target and biomarker for a variety of diseases, its development as a drug remains a challenging task. The identification of small molecule inhibitors that can specifically target DNAH17-AS1 and its regulation of gene expression, apoptosis, and cellular processes is an important step in its development as a potential drug.

Conclusion

DNAH17-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology make it an attractive target for drug development due to its ability to regulate the expression of genes and its involvement in various cellular processes. Further research is needed to identify small molecule inhibitors that can specifically target DNAH17-AS1 and its regulation of gene expression, apoptosis, and cellular processes.

Protein Name: DNAH17 Antisense RNA 1

The "DNAH17-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAH17-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets